he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:中风患儿死亡简析
- 2022-05-03Nature:美国最新研究有望改善过敏性疾病的临床和治疗
- 2022-04-252013年国际抗癫痫联会抗癫痫药使用指南
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- Cell重磅:解决了近百年的问题!研究发现了闪过记忆的潜在机制
- 婴儿身上的白斑是白癜风吗?
- 控制癫痫患者再次抽搐,不包括可选药物?
- 由于医生的原因,物「沉默」而且很难进入处方
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- JAAD:紫外线光疗会增加湿疹患者皮肤癌的发病率吗?
- 2013国际抗癫痫联合会抗癫痫药用指南
- 钙化是怎么回事?如何治疗钙化?
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫猝死:凶手是谁?
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 男人的寿命与做这件事的频率有关
- 不同类型的肾盂肾炎治疗 肾盂肾炎
- 慢性炎症状 关注男性健康
- 脑梗死的症状是什么有这些前兆要谨慎
- 如何最有效地去除黑头?
- 白癜风光疗有很多方法 因地制宜教你选择
- 癫痫治疗障碍仍难以克服
- 继发性癫痫能治愈吗 治疗癫痫有几个步骤
- 扬子江药业评价信息:同日两品种获批上市!今年,共有86个品种的评价
- 第一批国家级 癫痫中心单位获得认证并授权
- 妇幼医院综合外科开始分专业注册诊疗!
- 肾坏了 4大偏方补肾透支
- 为什么光疗能有效治疗白癜风?
- 注射激素会导致外周色素减少和萎缩
- 乳腺癌的早期症状 溢液应小心!
- 大脑缺氧 大脑缺氧的呕吐
- 20130730云南养生会:沈洪俊讲癫痫病的最初症状
- 妇女癫痫的症状是什么呢
- 癫痫病应该怎样病患 癫痫病病患要多少钱
- 身体健康能治癫痫病吗
- 手术学习:内镜下经三脑室入路病患颅内脊索瘤
- 癫痫病会遗传吗 癫痫的治疗方式
- 癫痫病到底有哪几种特性呢 癫痫的症状有什么
- 羊癫疯能治好吗 治疗不易须要多加注意防止发作
- 疗程癫痫病有特效药
- 樟脑丸成分 樟脑丸有哪些疗效
- 癫痫病有什么办法化疗 针对病因做化疗
- 怎么病人癫痫病有最新方法吗